NCT07729046

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

RecruitingPHASE2INTERVENTIONAL

Trial Details

Start: 2027-07Est. Completion: 2032-05

Enrollment target: 150 participants

Locations

UC San Diego Health Moores Cancer Center, La Jolla, California, United States

Contact

Asona Lui, MD, PhDajlui@health.ucsd.edu 858-822-4319

Alyssa Beck, MDa4beck@health.ucsd.edu 858-657-7000

Other microbiome trials you might be interested in

Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast CancerPhase 2Recruiting

Invasive Breast Cancer

This is a single-arm, open-label, phase 2 study that will enroll 36 subjects, who have pathologically proven diagnosis o…

Milwaukee, United StatesEst. completion Aug 11, 2025

View Trial →

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsPhase 2Recruiting

Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed AdenocarcinomaBladder Neuroendocrine CarcinomaBladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaChromophobe Renal Cell Carcinoma

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.